Lung Cancer
Volume 45 , Pages S17-S20 , August 2004

Malignant pleural mesothelioma in Turkey, 2000–2002

References 

  1. Karakoca Y, Emri S, Cangır AK, Barıs YI. Environmental pleural plaques due to asbestos and fibrous zeolite exposure in Turkey. Indoor Built Environ. 1997;6:100–105
  2. Dogan M, Emri S. Environmental health problems related to mineral dusts in Ankara and Eskisehir, Turkey. Yerbilimleri. 2000;22:149–161
  3. Baris YI, Simanato l, Artvinli M, Pooley F, Saracci R, Skidmore J, et al.  Epidemiological and environmental evidence of health effect of exposure to erionite fibers: a four-year study in the Cappadocian region of Turkey. Int. J. Cancer. 1987;39:10–17
  4. Carthew P, Hill RJ, Edwards RE, Lee PN. Intrapleural administration of fibers induces mesothelioma in rats in the same relative order of hazards as occurs in man after exposure. Hum. Exp. Toxicol. 1992;11:530–534
  5. Dumortier P, Çoplü L, de Maertelaer V, Emri S, Baris I, De Vuyst P. Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. Am. J. Respir. Crit. Care Med. 1998;158:1815–1824
  6. Dumortier P, Coplu L, Broucke I, Emri S, Selcuk T, de Maertelaer V, et al.  Erionite bodies and fibres in bronchoalveolar lavage fluid (BALF) of residents from Tuzköy, Cappadocia, Turkey. Occup. Environ. Med. 2001;58:261–266
  7. Senyigit A, Babayigit C, Gokirmak M, Topcu F, Asan E, Coskunsel M, et al.  Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the Southeast of Turkey. Respiration. 2000;67:610–614
  8. Baris B, Demir AU, Shehu V, Karakoca Y, Kısacık G, Baris YI. Environmental fibrous (zeolite/erionite) exposure and malignant tumors other than mesothelioma. J. Environ. Path. Tox. Oncol. 1996;15:183–189
  9. Metintas M, Hillerdal H, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow up of a Turkish cohort. Eur. Respir. J. 1999;13:523–526
  10. Baris YI. Lung diseases related to asbestos and fibrous zeolite exposure in Turkey. The symposium on nutrition, environment, and cancer, 31 March–3 April 2002, Ankara, Turkey.
  11. Selcuk ZT, Çöplü L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 1992;102:790–796
  12. Emri S, Demir A, Dogan M, Akay H, Bozkurt B, Carbone M, et al.  Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol. Lett. 2002;127(1–3):251–257
  13. Dogan AU. Cappadocian mesothelioma villages. The symposium on nutrition, environment, and cancer, 31 March–3 April 2002, Ankara, Turkey.
  14. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357:444–445
  15. Carbone M, Fisher S, Powers A, Pass HI, Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J. Cell. Physiol. 1999;180:167–172
  16. Emri S, Kocagoz T, Olut A, Güngen Y, Mutti L, Baris YI. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. Anticancer Res. 2000;20:891–894
  17. Olut A, Ertugrul D, Kocagoz T, Er M, Emri S. HHV-8 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma. Monaldi. Arch. Chest. Dis. 2000;55:110–113
  18. Ozdemir O, Emri S, Karakoca Y, Sayinalp N, Akay H, Dundar S, et al.  Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma. Thromb. Res. 1996;84:121–128
  19. Tansan S, Emri S, Selcuk T, Koc Y, Hesketh P, Heeren T, et al.  Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology. 1994;51:348–351
  20. Emri S, Akbulut H, Zorlu F, Dincol D, Akay H, Gungen Y, et al.  Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer. 2001;33:109–114
  21. Olut A, Fırat P, Ertugrul D, Gungen Y, Emri S. Ras oncoprotein expression in erionite-and asbestos-induced Turkish malignant pleural mesothelioma patients-a pilot study. Resp. Med. 2001;95:697–698
  22. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, et al.  Phase I clinical and pharmacokinetic study of premetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2002;20:3533–3544
  23. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al.  Phase II study of premetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 2003;21:1556–1561

PII: S0169-5002(04)00165-5

doi: 10.1016/j.lungcan.2004.04.009

Lung Cancer
Volume 45 , Pages S17-S20 , August 2004

Article Tools